Clinical trial
The Effect of Mesenchymal Stem Cell Secretome on Inflammation Activity and Markers in Sjogren Syndrome: A Randomized, Placebo-Controlled, Double-Blind Trial
NCT07910526 is registered in ClinicalTrials.gov with Universitas Sebelas Maret Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Mesenchymal Stem Cell Secretome on Inflammation Activity and Markers in Sjogren Syndrome: A Randomized, Placebo-Controlled, Double-Blind Trial
- Lead sponsor
- Universitas Sebelas Maret Hospital
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- May 1, 2024
- Completion date
- October 20, 2026
- Enrollment
- 29 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
UC-MSC Secretome
-
Placebo (0.9% NaCl)
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) score
Lead sponsor's other trials
Universitas Sebelas Maret Hospital, most recent start first.
Similar trials
Same condition (Sjogren's Syndrome) and phase, most recent start first.
+12 more trials See the condition page